TRUMF - Terumo Corporation (TRUMF) Q3 2021 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) Q3 2021 Earnings Conference Call February 10,2022, 6:00 AM ET Company Participants Naoki Muto – Chief Accounting & Financial Officer Conference Call Participants Presentation Naoki Muto I'm the CFO, Muto. I will now explain the third quarter results for the fiscal year ending March 2022. First, the highlights from the quarter. Q3 stand-alone revenue grew 8% from the previous year. Year-to-date revenue also grew 17%. The Cardiac and Vascular Company entered a COVID-19 recovery pattern, growing 12% from the previous year. With strong demand, Blood and Cell Technologies Company grew the next most. Adjusted operating profit slowed slightly in the third quarter amid continued production adjustment to normalized inventory down from COVID safety stock levels, as well as impact from higher freight and raw materials cost caused by global supply chain disruption. Year-to-date profit grew 21% from the previous year. In light of these third quarter results,

For further details see:

Terumo Corporation (TRUMF) Q3 2021 Results - Earnings Call Transcript